|
Synonyms: SYL-1001 | SYL1001
Compound class:
Nucleic acid
|
| No information available. |
Summary of Clinical Use ![]() |
| Tivanisiran (SYL1001) was progressed as an opthalmic clinical candidate to evaluate its potential to reduce ocular (inflammation-induced) pain in dry eye disease [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05310422 | Safety Study of Tivanisiran to Treat Dry Eye | Phase 3 Interventional | Sylentis, S.A. | ||
| NCT04819269 | Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome | Phase 3 Interventional | Sylentis, S.A. | ||